Psyence Biomedical Stock to Reverse Split on Tuesday, January 20th (NASDAQ:PBM)

Shares of Psyence Biomedical Ltd. (NASDAQ:PBM) are scheduled to reverse split on Tuesday, January 20th. The 1-6.25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, January 19th.

Psyence Biomedical Stock Performance

Shares of NASDAQ:PBM opened at $0.67 on Friday. The company’s fifty day moving average is $1.48 and its 200-day moving average is $3.18. Psyence Biomedical has a 52 week low of $0.65 and a 52 week high of $17.44. The company has a market capitalization of $1.25 million, a PE ratio of 0.17 and a beta of 0.32.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Psyence Biomedical in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Psyence Biomedical stock. Virtu Financial LLC acquired a new position in shares of Psyence Biomedical Ltd. (NASDAQ:PBM) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,325 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.55% of Psyence Biomedical as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 77.44% of the company’s stock.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.